NAMS
NewAmsterdam Pharma Co N.V.
Key Financials
Net Income
$-203819000
↑ 15.6%
Revenue
$22.5M
↓ 50.6%
Operating Income
$-225683000
↓ 28.0%
Total Liabilities
$85.9M
↓ 19.9%
EPS (Diluted)
$-1.72
↑ 32.8%
Shareholders' Equity
$683.4M
↓ 9.8%
Total Assets
$769.3M
↓ 11.0%
Cash & Equivalents
$490.0M
↓ 36.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 10/2/2026 | View on SEC |
| 8-K | 9/29/2026 | View on SEC |
| SCHEDULE 13D/A | 9/22/2026 | View on SEC |
| 8-K | 9/21/2026 | View on SEC |
| 4 | 9/15/2026 | View on SEC |
| 4 | 9/9/2026 | View on SEC |
| 4 | 9/3/2026 | View on SEC |
| 144/A | 8/25/2026 | View on SEC |
| 4 | 8/25/2026 | View on SEC |
| 144 | 8/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NAMS |
| Company Name | NewAmsterdam Pharma Co N.V. |
| CIK | 1936258 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | P7 |
| Phone | 35 206 2971 |